Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
62°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Verve Therapeutics
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve Therapeutics Announces Updates on its PCSK9 Program
April 02, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 28, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 01, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 01, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement
December 01, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
November 28, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
November 28, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia
November 12, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3
October 31, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia
October 23, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association’s Scientific Sessions 2023
September 26, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
September 21, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer
September 18, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results
August 10, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference
August 03, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
June 01, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve Therapeutics to Participate in the Stifel 2023 Tailoring Genes: Virtual Genetic Medicines Day
May 23, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results
May 15, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve Therapeutics to Participate in the RBC Capital Markets 2023 Global Healthcare Conference
May 09, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
March 27, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates
March 03, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
March 02, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve Therapeutics Announces VERVE-101 Awarded Innovation Passport by the UK MHRA for the Treatment of Heterozygous Familial Hypercholesterolemia
February 14, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve Therapeutics to Participate in Upcoming Investor Conferences
November 11, 2022
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results
November 07, 2022
From
Verve Therapeutics
Via
GlobeNewswire
Tickers
VERV
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.